Skip to main content
. 2019 May 15;11(5):2775–2783.

Figure 7.

Figure 7

Sitagliptin suppresses advanced glycation end-products (AGEs)-induced degradation of aggrecan in human primary chondrocytes (HPCs). HPCs were treated with 100 μg/ml AGEs in the presence or absence of 100, 200 nM sitagliptin for 48 h. Expression of aggrecan was determined by western blot analysis (a, b, c, P<0.01 vs. previous column group).